Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 27 Jun 24 424B3 Prospectus supplement
- 3 Jun 22 424B5 Prospectus supplement for primary offering
- 1 Jun 22 424B5 Prospectus supplement for primary offering
- 7 Apr 22 424B3 Prospectus supplement
- 14 Feb 22 EFFECT Notice of effectiveness
- 9 Feb 22 S-3/A Shelf registration (amended)
-
4 Feb 22 S-3 Shelf registration
INM similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
InMed Pharmaceuticals Inc.
We consent to the use of our report dated September 24, 2021, with respect to the consolidated financial statements of InMed Pharmaceuticals Inc. incorporated by reference herein and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
Chartered Professional Accountants
Vancouver, Canada
February 4, 2022